ARCHIVES

Adjuvant XELOX More Effective Than 5-FU/LV For Stage III Colon Cancer

This article is from The Cancer Letter archive.

Vol. 33 No. 1 | January 29, 2010

Download PDF Visit The Full Archive

Related Articles

20% of Women Do Not Believe Tailored Risk Assessments

August 30, 2013

Cancer Patients Satisfied With Experience In Clinical Trials, Survey Of 2,000 Finds

July 28, 2006

Study Finds Hormonal Therapy Reduces Risk Of Disease Progression In Prostate Cancer

July 27, 2001

Surgeons Responsible For Improving Their Role, CCIRC Says

July 8, 1977

Prognostic Factors Don’t Explain Better Prostate Cancer Survival In Most Asian Men

August 31, 2007

NCI advisory panel recommends funding a 10-year Human Cancer Genome Project with $1.35 billion in new money.

March 18, 2005